Crenolanib is an investigational pharmaceutical compound that functions as a tyrosine kinase inhibitor. It is being studied in clinical trials for various cancer types, including acute myeloid leukemia, gastrointestinal stromal tumor, and glioma.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 670220-88-9
Neratinib
tyrosine kinase inhibitor
XL-228
tyrosine kinase inhibitor
N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
tyrosine kinase inhibitor
Repotrectinib
tyrosine kinase inhibitor
3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
active pharmaceutical ingredient
Metirosine, (R)-
active pharmaceutical ingredient
Metirosine
catecholamine synthesis inhibitor
DPPG-Na
active pharmaceutical ingredient
1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DYNHJHQFHQTFTP-UHFFFAOYSA-N
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4